-
In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year.
-
A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer.
-
For patients with BRCA-associated breast cancer, it had been previously demonstrated that a second breast cancer occurs in approximately one-third of patients by 15 years after diagnosis, and that this risk was reduced significantly by contralateral mastectomy.
-
In a multicenter, randomized, double-blind, placebo-controlled clinical trial of bevacizumab added to standard temozolomide and radiation therapy for patients with glioblastoma multiforme, progression-free survival but not overall survival was enhanced.
-
In a well-controlled retrospective analysis of patients who presented with metastatic colorectal cancer, primary tumor resection was associated with improved overall survival.
-
Bevacizumab added to chemotherapy, particularly paclitaxel and cisplatin, was efficacious in all response outcomes (objective response, progression-free survival, and overall survival) without diminution in quality of life or unacceptable toxicity.
-
The FDA has approved the first nasally administered flu vaccine to be marketed in this country. Medimmunes FluMist is also the first influenza vaccine to use live virus.
-
Following radiation therapy, adjuvant extrafascial hysterectomy decreased the risk of relapse for patients with bulky stage IB cervical cancer without improving survival.
-
Since the introduction of the 3-weekly CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) chemotherapy 25 years ago, many efforts have been undertaken to improve the efficacy of multicycle polychemotherapy for patients with aggressive lymphoma.
-
The development of an isolated supraclavicular node recurrence of breast cancer after primary surgical resection (including axillary node dissection) was found, upon review of the tumor registries of 8 community hospitals in The Netherlands, to occur very uncommonly (less than 1%). Examination of clinical outcomes for these patients indicates that isolated supraclavicular recurrence is an antecedent of disseminated disease, in that, even with local control (as achieved by radiation therapy), the great majority of patients soon develop systemic disease.